Bavarian Nordic (CO:BAVA) — Market Cap & Net Worth
Market Cap & Net Worth: Bavarian Nordic (BAVA)
Bavarian Nordic (CO:BAVA) has a market capitalization of $2.43 Billion (Dkr15.56 Billion) as of September 16, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #5536 globally and #33 in its home market, demonstrating a -5.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bavarian Nordic's stock price Dkr203.00 by its total outstanding shares 76638672 (76.64 Million). Also see Bavarian Nordic asset portfolio for a full breakdown of the balance sheet.
Bavarian Nordic Market Cap History: 2015 to 2026
Bavarian Nordic's market capitalization history from 2015 to 2026. Data shows change from $3.39 Billion to $2.43 Billion (-0.48% CAGR). Also see Bavarian Nordic (BAVA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Bavarian Nordic Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bavarian Nordic's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BAVA stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.37x
Bavarian Nordic's market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.66x
Bavarian Nordic's market cap is 1.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.36 Billion | $1.01 Billion | $30.60 Million | 2.35x | 77.19x |
| 2017 | $2.13 Billion | $1.37 Billion | $181.34 Million | 1.55x | 11.73x |
| 2018 | $1.21 Billion | $500.62 Million | -$361.93 Million | 2.41x | N/A |
| 2019 | $1.63 Billion | $662.49 Million | -$346.78 Million | 2.45x | N/A |
| 2020 | $2.24 Billion | $1.85 Billion | $277.52 Million | 1.21x | 8.08x |
| 2021 | $3.22 Billion | $1.90 Billion | -$464.77 Million | 1.70x | N/A |
| 2022 | $2.56 Billion | $3.15 Billion | -$347.38 Million | 0.81x | N/A |
| 2023 | $2.13 Billion | $7.06 Billion | $1.48 Billion | 0.30x | 1.44x |
| 2024 | $2.27 Billion | $5.72 Billion | $987.98 Million | 0.40x | 2.30x |
| 2025 | $2.29 Billion | $6.17 Billion | $1.38 Billion | 0.37x | 1.66x |
Competitor Companies of BAVA by Market Capitalization
Companies near Bavarian Nordic in the global market cap rankings as of September 16, 2026. Review how tangible is Bavarian Nordic's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bavarian Nordic by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Bavarian Nordic Historical Marketcap From 2015 to 2026
Between 2015 and today, Bavarian Nordic's market cap moved from $3.39 Billion to $ 2.43 Billion, with a yearly change of -0.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr2.43 Billion | +6.37% |
| 2025 | Dkr2.29 Billion | +0.79% |
| 2024 | Dkr2.27 Billion | +6.71% |
| 2023 | Dkr2.13 Billion | -16.85% |
| 2022 | Dkr2.56 Billion | -20.61% |
| 2021 | Dkr3.22 Billion | +43.74% |
| 2020 | Dkr2.24 Billion | +37.88% |
| 2019 | Dkr1.63 Billion | +34.52% |
| 2018 | Dkr1.21 Billion | -43.18% |
| 2017 | Dkr2.13 Billion | -9.92% |
| 2016 | Dkr2.36 Billion | -30.35% |
| 2015 | Dkr3.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Bavarian Nordic was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.43 Billion USD |
| MoneyControl | $2.43 Billion USD |
| MarketWatch | $2.43 Billion USD |
| marketcap.company | $2.43 Billion USD |
| Reuters | $2.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more